Chagas Disease Management Market Size to Witness Huge Growth by 2025Posted by Shristi on October 4th, 2019 Analyst Speak: “The Global Chagas Disease Management Market was valued around US$ XX Mn by 2018 and growing at a significant CAGR of XX% over next seven years 2019-2025 owing to growing incidence of chagas disease due to unhygienic conditions” The global chagas disease management market accounted for US$ XX Mn in 2018 and burgeoning over the forthcoming years. Factors which are influencing the market growth are growing investments in the field of research and development of new products, increasing prevalence of chagas disease owing to unhygienic conditions and increase in the chagas disease population. However, lack of awareness about the treatment of Chagas disease, very limited number of products approved and supply chain issues with chagas disease drugs are hampering the market growth. Global chagas disease management market segmented on the basis of treatment type, drug type, distribution channel and region. Avail Sample Report of the Market @ https://www.precisionbusinessinsights.com/request-sample?product_id=15817 Benznidazole Dominate the Global Chagas Disease Management Market Based on drug type, global chagas disease management market segmented into benznidazole and nifurtimox. Benznidazole segment held considerable market growth during estimated period. Benznidazole is typically used as treatment for Chagas disease. Benznidazole is indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease. Benznidazole prominently reduce the parasitemia, which constitutes an important factor linked to vertical transmission. Early usage of benznidazole in Chagas disease treatment results in better clinical and parasitological outcomes. North America Leads the Global Chagas Disease Management market PBI’s global chagas disease management market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to regional analysis, North America and Europe are the key markets for chagas disease management. North America dominated the market revenue share for Chagas disease management owing to rising prevalence and incidence of Chagas disease in the region. According to CDC, the prevalence of Chagas disease in North America was around 300,000 people in 2016. Latin America is expected to grow with a significant CAGR owing to increasing prevalence of Chagas disease in the region. According to WHO, around 8 million people are suffering from Chagas disease. Strategic Collaboration are the Key Strategies Adopted by Market Players Global chagas disease management market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. In March 2017, Daiichi Sankyo Company Limited and Drugs for Neglected Diseases initiative (DNDi) are collaborated to form a joint research with regard to a new research program, the hit-to-lead project to develop the drugs for Chagas disease and leishmaniasis. Key player’s profiles in the report are Novartis AG (Switzerland), Laboratorio Elea S.A.C.I.F. y A (Argentina), Kancera AB (Sweden), KaloBios Pharmaceuticals, Inc. (U.S.), Grupo Praxis Pharmaceutical SA (Spain), GlaxoSmithKline Plc. (U.K), Eisai Co Ltd (Japan), Daiichi Sankyo Company Ltd (Japan), Bayer AG (Germany) and AstraZeneca (U.K). For More Information @ https://www.precisionbusinessinsights.com/market-reports/chagas-disease-management-market/ Precision Business Insights (PBI) in its report titled “Global Chagas Disease Management Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Moreover, the report also includes the total revenue and volume for the market. Detailed Segmentation By Drug Type
By Treatment Type
By Distribution Channel
By Geography North America
Europe
Asia-Pacific
Latin America
Middle East and Africa (MEA)
About Us: Like it? Share it! More by this author |